LONDON, March 15, 2016 /PRNewswire/ -- Analysis of the US Autoimmune Disease Diagnostics Market : Systemic Autoimmune Diseases Spur a Double-digit Market Growth Rate of 14.2%
According to the National Institute of Health (NIH), there are more than 80 types of autoimmune diseases, of which less than 30 are diagnosable. Being 1 of the top 10 causes of death in the United States, there is a critical need in the market for the diagnosis and the treatment of both systemic diseases, such as lupus and rheumatoid arthritis, as well as localized diseases, such as celiac, IBD, IBS, and Hashimoto's. Systemic diseases dominate the market due to their high prevalence in the United States and also because of the market participation of large diagnostics companies, such as Inova Diagnostics, Siemens Healthcare, Abbott Diagnostics, and Beckman Coulter. The localized disease segment is the fastest-growing, mainly due to celiac, as gluten intolerance in the United States is increasing at an exponential rate.
Key Predictions: US Autoimmune Disease Diagnostics Market
Total Autoimmune Disease Diagnostics Market: Key Predictions, US, 2015
The market generated a revenue of $ million in 2015 and is expected to reach $ million in 2020, at a compound annual growth rate (CAGR) of %, spurred by localized diseases, such as celiac, which is expected to grow at % in the United States. Systemic diseases, such as systemic lupus erythematosus (SLE) and RA will remain the highest revenue contributors to the market.
Companies that have multiplexing systems and sensitive nucleic acid amplification technique (NAT)-based assays will be able to meet the need for accurate diagnosis and quick turnaround time when compared to companies that use automation systems like enzymelinked immunosorbent assay (ELISA), which will be reflected in the increasing adoption of NAT-based platforms.
Despite Theranos Inc.'s failure at direct-to-consumer tests, the model still persists in the industry. Gluten allergy tests can be purchased directly by consumers, which will disrupt the lab testing market through test volume revenue loss.
The top market shareholders will expand their revenue by investing in other revenue channels by partnering with pharmaceutical companies for companion diagnostics. Autoimmune diagnostics will no longer be considered a niche market. In vitro diagnostic companies that are established with automation devices will expand their portfolio to cover this market.
An increasing number of platforms will include the genetic analysis component in addition to immunoassays. The accuracy of the results offered by these systems will be increasingly utilized for therapy selection for the personalized treatment of autoimmune disorders.
Download the full report: https://www.reportbuyer.com/product/3691043/
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers